# Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

> **NCT01433731** · PHASE1 · COMPLETED · sponsor: **TetraLogic Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** placebo for SHAPE (SHP-141)
- **DRUG:** SHAPE (SHP-141) 0.1% BID
- **DRUG:** SHAPE (SHP-141) 0.5% BID
- **DRUG:** SHAPE (SHP-141) 1.0% BID

## Key facts

- **NCT ID:** NCT01433731
- **Lead sponsor:** TetraLogic Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433731, "Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01433731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*